Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..

NCT07408908 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Cutaneous Lupus Erythematosus

Interventions

DRUG: ACT100 Injection
DRUG: Placebo for ACT100
DRUG: ACT100 Injection
DRUG: Placebo for ACT100
DRUG: ACT100 Injection
DRUG: Placebo for ACT100
DRUG: ACT100 Injection
DRUG: Placebo for ACT100
DRUG: ACT100 Injection
DRUG: Placebo for ACT100
DRUG: ACT100 Injection
DRUG: Placebo for ACT100

Sponsor

Xiamen Amoytop Biotech Co., Ltd.

Collaborators

[object Object]